While initial studies indicated a correlation between HER2/neu amplification and adverse prognosis and recurrence in breast cancer patients (Slamon et al., 1987), guidelines set forth by the American Society of Clinical Oncology (ASCO) underscore that HER2 status should primarily guide the selection of suitable treatment modalities rather than serve as a prognostic indicator. This evidence concerns the gene ERBB2 and breast carcinoma.